Abstract: DOI: 10.14744/ejmo.2021.16263 EJMO 2021;5(1):63–70 Research Article A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients Abu Taiub Mohammed Mohiuddin Chowdhury,1 Guo Dan,1 Shuixiang He1 Mohammad Shahbaz,2 Md Rezaul Karim,3 Jahirul Islam, Department of Gastroenterology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China Chakoria Upazilla Health Complex, Cox’s Bazar, Bangladesh 3 Biomedical Research Institute of Hubei University of Medicine, Shiyan, China 4 Department of Epidemiology and Health Statistics, Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China 1 2 Abstract Objectives: We investigated the outcomes of Ivermectin-Doxycycline vs. Hydroxychloroquine-Azithromycin combination therapy in mild to moderate COVID19 patients. Methods: Patients were divided randomly into two groups: Ivermectin 200µgm/kg single dose + Doxycycline 100mg BID for ten days in group A, and Hydroxychloroquine 400mg for the first day, then 200mg BID for nine days + Azithromycin 500mg daily for five days in group B (Control group). RT-PCR for SARS-CoV-2 infection was repeated in all symptomatic patients on the second day onward without symptoms. Repeat PCR was done every two days onward if the result found positive. Time to the negative PCR and symptomatic recovery was measured for each group. Results: All subjects in Group A reached a negative PCR, at a mean of 8.93 days, and reached symptomatic recovery, at a mean of 5.93 days, with 55.10% symptom-free by the fifth day. In group B, 96.36% reached a negative PCR at a mean of 9.33 days and were symptoms-free at 6.99 days. In group A 31.67% of patients expressed symptoms caused by medication, this was 46.43% in group B. Conclusion: The combination therapy of Ivermectin-Doxycycline showed a trend towards superiority to the combination of Hydroxychloroquine-Azithromycin for mild to moderate COVID19 disease. Keywords: Azithromycin, Bangladesh, COVID-19, Doxycycline, Hydroxychloroquine, Ivermectin, randomized controlled trial (RCT) Cite This Article: Mohiuddin Chowdhury ATM, Shahbaz M, Karim MR, Islam J, Dan G, He S. A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients. EJMO 2021;5(1):63–70. C oronavirus disease 2019 (COVID-19) is a global pandemic declared by the world health organization (WHO). Over ninety million people have already been infected by severe acute respiratory syndrome‐corona- virus‐2 (SARS-CoV-2), and billions have been affected by the socioeconomic squeal. As SARS-CoV-2 is a novel virus, there are no proven treatment options yet. Early treatment before the disease becomes severe would be optimal. The Address for correspondence: Shuixiang He, MD; PhD. Department of Gastroenterology, First affiliated hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China Phone: 008613991380928 Email: dyyyjxk@xjtu.edu.cn Abu Taiub Mohammed Mohiuddin Chowdhury, MD. Department of Gastroenterology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China Phone: 008801817711079; 008615529366232 E-mail: dr_mohiuddinchy@yahoo.com Submitted Date: January 21, 2021 Accepted Date: February 15, 2021 Available Online Date: February 25, 2021 © Copyright 2021 by Eurasian Journal of Medicine and Oncology - Available online at www.ejmo.org OPEN ACCESS This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International..